Cargando…

PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer

Background: Immune checkpoint inhibitors (ICIs) have become the standard treatment for advanced non-small cell lung cancer (NSCLC). ICIs can provide durable responses and prolong survival for some patients. With the increasing routine of next-generation sequencing (NGS) in clinical practice, it is e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Zhixuan, Wang, Li, Leng, Chaohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497019/ https://www.ncbi.nlm.nih.gov/pubmed/37602864 http://dx.doi.org/10.18632/aging.204964

Ejemplares similares

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini, Nicholas, et al.
Publicado: (2021)

Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications
por: Jiang, Yunyun, et al.
Publicado: (2013)

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC
por: Sun, Yiting, et al.
Publicado: (2021)

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types
por: Shang, Xiaoling, et al.
Publicado: (2022)

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
por: Hsu, Hung-Chih, et al.
Publicado: (2018)

Genetic variants in PTPRD and risk of gestational diabetes mellitus
por: Chen, Ting, et al.
Publicado: (2016)

PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas
por: Rautajoki, Kirsi J., et al.
Publicado: (2022)

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
por: Torasawa, Masahiro, et al.
Publicado: (2023)

Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer
por: Peyser, Noah D., et al.
Publicado: (2015)

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer
por: Liao, Dehua, et al.
Publicado: (2022)

Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis
por: Ortiz, Berenice, et al.
Publicado: (2014)

Reduced Expression of PTPRD Correlates with Poor Prognosis in Gastric Adenocarcinoma
por: Wang, Dandan, et al.
Publicado: (2014)

Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades
por: Wang, Xiaoyan, et al.
Publicado: (2021)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
por: Brueckl, Wolfgang M., et al.
Publicado: (2020)

Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors
por: Wang, Li, et al.
Publicado: (2021)

Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies
por: Chibnik, Lori B, et al.
Publicado: (2017)

DIAPH2, PTPRD and HIC1 Gene Polymorphisms and Laryngeal Cancer Risk
por: Śnit, Mirosław, et al.
Publicado: (2021)

Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
por: Guo, Xiaojin, et al.
Publicado: (2022)

Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
por: Deng, Chao, et al.
Publicado: (2021)

Evidence that homozygous PTPRD gene microdeletion causes trigonocephaly, hearing loss, and intellectual disability
por: Choucair, Nancy, et al.
Publicado: (2015)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study
por: Tenuta, Marta, et al.
Publicado: (2021)

PTPRD silencing by DNA hypermethylation decreases insulin receptor signaling and leads to type 2 diabetes
por: Chen, Yng-Tay, et al.
Publicado: (2015)

PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin
por: Bae, Won Jung, et al.
Publicado: (2019)

Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients
por: Wang, Chin-Chou, et al.
Publicado: (2017)

The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development
por: Sacdalan, Danielle Benedict, et al.
Publicado: (2021)

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

ICIS05 CONFERENCE
por: Lau, C, et al.
Publicado: (02/1)

The Icy Realm of the Rime
por: Potter, Polyxeni
Publicado: (2011)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Mice lacking Ptprd exhibit deficits in goal-directed behavior and female-specific impairments in sensorimotor gating
por: Ho, Emily V., et al.
Publicado: (2023)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
por: Xiang, Jing, et al.
Publicado: (2023)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

Aumolertinib challenge as an optional treatment in advanced non small-cell lung cancer after osimertinib failure with epidermal growth factor receptor-sensitive mutation: A case series
por: Ding, Xinjing, et al.
Publicado: (2022)

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer
por: Tjokrowidjaja, Angelina, et al.
Publicado: (2022)

Enceladus and the icy moons of Saturn
por: Schenk, Paul M, et al.
Publicado: (2018)

Ici, priorité ... aux piétons !
Publicado: (2002)

L'espion d'ici
por: Omnes, Roland
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_28dpvmpc61hg8rl8vsq9vfidno